NASDAQ:EMBC Embecta (EMBC) Stock Price, News & Analysis $13.55 -0.15 (-1.09%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Embecta Stock (NASDAQ:EMBC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Embecta alerts:Sign Up Key Stats Today's Range$13.49▼$13.6950-Day Range$12.47▼$16.5052-Week Range$9.93▼$19.79Volume191,658 shsAverage Volume417,412 shsMarket Capitalization$781.43 millionP/E Ratio11.29Dividend Yield4.43%Price Target$12.00Consensus RatingReduce Company OverviewEmbecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.Read More… $25,000 into $109,616 in two months? (Ad)Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. Embecta Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks48th Percentile Overall ScoreEMBC MarketRank™: Embecta scored higher than 48% of companies evaluated by MarketBeat, and ranked 673rd out of 1,012 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.8 / 5Analyst RatingReduce Consensus RatingEmbecta has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageEmbecta has received no research coverage in the past 90 days.Read more about Embecta's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-6.17% Earnings GrowthEarnings for Embecta are expected to decrease by -6.17% in the coming year, from $2.43 to $2.28 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Embecta is 11.29, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.32.Price to Earnings Ratio vs. SectorThe P/E ratio of Embecta is 11.29, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 139.15.Read more about Embecta's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.98% of the float of Embecta has been sold short.Short Interest Ratio / Days to CoverEmbecta has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Embecta has recently decreased by 17.86%, indicating that investor sentiment is improving significantly. Dividend3.3 / 5Dividend StrengthStrong Dividend LeadershipEmbecta is a leading dividend payer. It pays a dividend yield of 4.68%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthEmbecta does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Embecta is 49.59%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Embecta will have a dividend payout ratio of 26.32% next year. This indicates that Embecta will be able to sustain or increase its dividend.Read more about Embecta's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.98% of the float of Embecta has been sold short.Short Interest Ratio / Days to CoverEmbecta has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Embecta has recently decreased by 17.86%, indicating that investor sentiment is improving significantly. News and Social Media2.7 / 5News Sentiment0.95 News SentimentEmbecta has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Embecta this week, compared to 2 articles on an average week.MarketBeat Follows7 people have added Embecta to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Embecta insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.28% of the stock of Embecta is held by insiders.Percentage Held by Institutions93.83% of the stock of Embecta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Embecta's insider trading history. Receive EMBC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Embecta and its competitors with MarketBeat's FREE daily newsletter. Email Address EMBC Stock News HeadlinesAnalyzing Embecta (NASDAQ:EMBC) and OraSure Technologies (NASDAQ:OSUR)October 12, 2024 | americanbankingnews.comEmbecta (NASDAQ:EMBC) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comMassive shakeup in defense contractingThere is a little-known energy technology stock that has made an incredible breakthrough… Which could become crucial to the operations of the US Military. And right now there are plans for this stock to undertake a major test project at a US Air Force based in Alaska. Now, this incredible breakthrough is still in its earliest stages… Which means you still have a chance to get in while its trading for under $10.October 17, 2024 | DTI (Ad)Embecta Corp.: Navigating Through A Changing LandscapeSeptember 22, 2024 | seekingalpha.comBTIG Reaffirms Their Hold Rating on Embecta Corporation (EMBC)September 4, 2024 | markets.businessinsider.comRecommendation to Sell: Anticipated Costs and Competition Challenge Embecta’s New Pump ProgramSeptember 4, 2024 | markets.businessinsider.comEmbecta Corp. Announces FDA Clearance Of Its Disposable Insulin Delivery SystemSeptember 3, 2024 | markets.businessinsider.comembecta Announces FDA Clearance of its Disposable Patch Pump for Insulin Delivery Informed by the Unique Needs of People with Type 2 DiabetesSeptember 3, 2024 | globenewswire.comSee More Headlines EMBC Stock Analysis - Frequently Asked Questions How have EMBC shares performed this year? Embecta's stock was trading at $18.93 at the beginning of 2024. Since then, EMBC stock has decreased by 28.4% and is now trading at $13.55. View the best growth stocks for 2024 here. How were Embecta's earnings last quarter? Embecta Corp. (NASDAQ:EMBC) posted its quarterly earnings results on Friday, August, 9th. The company reported $0.74 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.46 by $0.28. The firm's quarterly revenue was down 4.8% compared to the same quarter last year. Who are Embecta's major shareholders? Top institutional investors of Embecta include Inspire Advisors LLC (0.05%), Creative Planning (0.05%), Inspire Investing LLC (0.05%) and SG Americas Securities LLC (0.03%). Insiders that own company stock include Devdatt Kurdikar, Jacob Elguicze, Jeffrey Z Mann and David F Melcher. View institutional ownership trends. How do I buy shares of Embecta? Shares of EMBC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Embecta own? Based on aggregate information from My MarketBeat watchlists, some other companies that Embecta investors own include Waste Connections (WCN), AUO (AUOTY), The RMR Group (RMR), DiamondRock Hospitality (DRH), American Water Works (AWK), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings8/09/2024Ex-Dividend for 9/13 Dividend8/27/2024Dividend Payable9/13/2024Today10/17/2024Next Earnings (Estimated)11/19/2024Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:EMBC CUSIPN/A CIK1872789 Webwww.embecta.com Phone201-847-6880FaxN/AEmployees2,200Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside-11.4%Consensus RatingReduce Rating Score (0-4)1.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$1.21 Trailing P/E Ratio11.29 Forward P/E Ratio5.58 P/E GrowthN/ANet Income$70.40 million Net Margins6.23% Pretax Margin5.02% Return on Equity-19.09% Return on Assets12.27% Debt Debt-to-Equity RatioN/A Current Ratio2.11 Quick Ratio1.61 Sales & Book Value Annual Sales$1.12 billion Price / Sales0.70 Cash Flow$3.84 per share Price / Cash Flow3.53 Book Value($14.34) per share Price / Book-0.94Miscellaneous Outstanding Shares57,670,000Free Float57,540,000Market Cap$781.43 million OptionableOptionable Beta0.98 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:EMBC) was last updated on 10/17/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredEquation for Profits: Volatility = OpportunityFREE Intro to Options Class Online Tonight Prosper Trading Academy | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Embecta Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Embecta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.